Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart ...

Axonics Modulation Technologies Inc receives Investment Bank Analyst Rating Update ByInvesting.com •Mar 10, 2025 Axonics Modulation Technologies Inc. receives Investment Bank Analyst Rating Update ...

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

IRVINE, Calif. - Axonics, Inc. (NASDAQ:AXNX), a medical technology company, has announced today that it received approval from Australia's Therapeutic Goods Administration (TGA) to ...

Axonics, Inc. (AXNX) reported Q4 EPS of $0.01, $0.25 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $86 million versus the consensus estimate of ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $2.67 per share a year ago.

Axonics Modulation Technologies (AXNX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2020. This widely-known ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.50 per share a year ago.